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Background-—Patientswithatrialﬁbrillation (AF) treatedwithoral anticoagulantsmaybeexposed to an increased riskof bleeding events.
TheHAS-BLED (Hypertension, Abnormal renal and liver function, Stroke, Bleeding, Labile INRs, Elderly, Drugs or alcohol) score is a simple,
well-established, clinical bleeding-risk prediction score. Recently, a new algorithm-based score was proposed, the GARFIELD-AF (Global
Anticoagulant in the Field–AF) bleeding score. We compared HAS-BLED and GARFIELD-AF scores in predicting adjudicated bleeding
events in a clinical trial cohort of patients with AF taking anticoagulants, in the ﬁrst external comparative validation of both scores.
Methods and Results-—We analyzed patients from the SPORTIF (Stroke Prevention Using an Oral Thrombin Inhibitor in Patients
With AF) III and V trials. All patients assigned to the warfarin arm with information to calculate the scores were considered.
Outcomes were major, major/clinically relevant nonmajor, and any bleeding. A total of 3550 warfarin-treated patients were
available for analysis. Of these patients, 2519 (71.0%) had a HAS-BLED score ≥3, whereas based on GARFIELD-AF median value,
2056 (57.9%) were categorized as “high score.” Both HAS-BLED and GARFIELD-AF C-indexes showed modest predictive value
(C-index [95% conﬁdence interval] for major bleeding, 0.58 [0.56–0.60] and 0.56 [0.54–0.57], respectively); however, GARFIELD-AF
was not predictive of any bleeding. The GARFIELD-AF bleeding score had a signiﬁcantly lower sensitivity and a negative
reclassiﬁcation for any bleeding compared with HAS-BLED, assessed by integrated discrimination improvement and net
reclassiﬁcation improvement (both P<0.001). HAS-BLED showed a 5% net beneﬁt for any bleeding occurrence.
Conclusions-—The algorithm-based GARFIELD-AF bleeding score did not show any signiﬁcant improvement in major and major/
clinically relevant nonmajor prediction compared with the simple HAS-BLED score. For clinical usefulness in prediction of any
bleeding, the HAS-BLED score showed a signiﬁcant net beneﬁt compared with the GARFIELD-AF. ( J Am Heart Assoc. 2018;7:
e009766. DOI: 10.1161/JAHA.118.009766.)
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T he use of oral anticoagulant (OAC) drugs in patients withatrial ﬁbrillation (AF) is highly effective for stroke
prevention in AF, but is associated with an increased risk
for bleeding events.1–3 Baseline evaluation and management
of bleeding risk, as well as the routine reevaluation during the
clinical follow-up, are pivotal for patients with AF to minimize
occurring bleeding events.4,5
Of the various clinical scores for bleeding risk stratiﬁcation,
the HAS-BLED score6 is appropriately used to ﬂag up patients
for more regular review and follow-up, as well as drawing
attention to modiﬁable bleeding risk factors.7,8 The HAS-BLED
score has been shown to be a superior strategy for bleeding
risk evaluation compared with an approach only focusing on
modiﬁable bleeding risk factors.9–11
From the Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom (M.P., G.Y.H.L.); Department of Neuroscience, IRCCS—Istituto di
Ricerche Farmacologiche Mario Negri, Milan, Italy (M.P.); Department of Cardiology, Hospital Clınico Universitario Virgen de la Arrixaca, Instituto Murciano de
Investigacion Biosanitaria (IMIB-Arrixaca), CIBER-CV, Murcia, Spain (J.M.R.-C., M.A.E.-P., F.M.); Department of Internal Medicine and Medical Specialties, Sapienza-
University of Rome, Rome, Italy (G.F.); Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK
(G.Y.H.L.); and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark (G.Y.H.L.).
An accompanying Table S1 is available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.118.009766
Correspondence to: Gregory Y. H. Lip, MD, Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom. E-mail:
g.y.h.lip@bham.ac.uk
Received May 8, 2018; accepted August 2, 2018.
ª 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for
commercial purposes.
DOI: 10.1161/JAHA.118.009766 Journal of the American Heart Association 1
ORIGINAL RESEARCH
In recent years, several other bleeding clinical risk scores
have been proposed, all of which show modest predictive
capacity, despite progressively more complex models.12 More
recently, a new bleeding risk score has been proposed to
predict major bleeding in patients with AF, derived from the
GARFIELD-AF (Global Anticoagulant in the Field–AF) registry,
called the GARFIELD-AF bleeding score.13
The aim of this article is to compare the predictive value of
HAS-BLED and GARFIELD-AF bleeding scores for adjudicated
bleeding events in a cohort of patients with AF taking warfarin
derived from a randomized controlled trial cohort.
Methods
We used the pooled study populations of the SPORTIF (Stroke
Prevention Using an Oral Thrombin Inhibitor in Patients With
AF) III and V trials. The original protocol and principal results
have been previously described.14–16 In brief, the SPORTIF
trials were 2 multicenter phase III clinical trials comparing the
efﬁcacy and safety of the direct thrombin inhibitor, ximela-
gatran, against warfarin in patients with nonvalvular AF.
Signed, informed consent was required from each participant
in accordance with protocol regulations approved by the local
review boards governing research involving human subjects
and the Declaration of Helsinki. Deidentiﬁed data sets with
patient-level information were obtained directly from
AstraZeneca, and all the analyses were performed indepen-
dently from the company. The analytic methods and study
materials could be made available to other researchers for
purposes of reproducing the results or replicating the
procedures on request to the corresponding author and
AstraZeneca. All patients assigned to the warfarin treatment
arms and with available data for the clinical variables used to
calculate the 2 bleeding prediction scores were included in
the present analysis.
Bleeding Scores Deﬁnition
The HAS-BLED score was calculated according to the original
methods.6 Major bleeding incidence according to HAS-BLED
score, as reported in the original derivation cohort,6 is
shown in Table S1. Labile international normalized ratio
criterion was deﬁned as a time in therapeutic range <65%.
The “impaired liver function” criterion was scored 0, because
liver dysfunction was an exclusion criterion from the original
SPORTIF trials protocol. A HAS-BLED score <3 was catego-
rized as “low risk,” whereas a HAS-BLED score ≥3 was
categorized as “high risk.”17 Similarly, the GARFIELD-AF
bleeding score was calculated according to the original
proposed scheme.13 According to the median value of the
score distribution, patients were categorized as GARFIELD-
AF “high score” (above the median value) and GARFIELD-AF
“low score” (including and below the median value).
Study Outcomes
We considered 3 bleeding end points, which were adjudicated
in this trial cohort. Major bleeding outcome was deﬁned by ≥1
of the following criteria: clinically overt bleeding with a
concomitant decrease in hemoglobin levels of >2 g/dL or
requiring blood transfusion of at least 2 units of whole blood
or erythrocytes; or a bleeding episode involving a critical site
(intracranial, intraspinal, intraocular, retroperitoneal, pericar-
dial, or nontraumatic intra-articular bleeding).14 All major
bleeding events were centrally adjudicated by a blind
independent oversight committee. Major/clinically relevant
nonmajor (CRNM) bleeding outcome was deﬁned as all the
investigator-reported major bleeding events, independently of
central adjudication. Any bleeding outcome was deﬁned as
any bleeding event, both major and minor, that occurred
during the study.
Statistical Analysis
Continuous variables were reported as median (interquartile
range), whereas categorical variables were expressed as
counts and percentages. Differences in survival according to
the bleeding risk categories, assessed by an intention-to-treat
Clinical Perspective
What Is New?
• In anticoagulated patients with atrial ﬁbrillation (AF), both
HAS-BLED and GARFIELD-AF (Global Anticoagulant in the
Field–AF) bleeding scores showed modest predictive ability
in predicting most bleeding outcomes.
• Use of the algorithm-based GARFIELD-AF bleeding score did
not show any improvement in prediction of major bleeding
and major/clinically relevant nonmajor bleeding compared
with the simple HAS-BLED score.
• In predicting the occurrence of any bleeding event, the HAS-
BLED score demonstrated improved net beneﬁt compared
with the GARFIELD-AF bleeding score.
What Are the Clinical Implications?
• This study represents the ﬁrst external independent valida-
tion of the GARFIELD-AF bleeding score, in a clinical trial
cohort with adjudicated bleeding outcomes.
• In the decision-making process of prescribing oral antico-
agulant therapy in patients with AF, bleeding risk should be
evaluated to address modiﬁable bleeding risk factors and
“ﬂag up” the high-risk patients for early review and follow-
up.
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approach, were analyzed using the log-rank test, and Kaplan-
Meier curve estimates were drafted accordingly. A Cox
proportional hazards analysis was used to evaluate the
occurrence of the 3 bleeding outcomes according to contin-
uous scores, adjusted for sex and type of AF. C-indexes were
estimated, with exact estimation of 95% conﬁdence interval
(CI), according to the method of DeLong et al.18
Discrimination and reclassiﬁcation abilities were evaluated
by the integrated discrimination improvement, the net
reclassiﬁcation improvement, and the median improvement,
as described by Pencina et al.19 Integrated discrimination
improvement and net reclassiﬁcation improvement have been
calculated using scores as continuous variables and according
to a time-dependent approach, whereas the clinical useful-
ness and net beneﬁt were estimated using the decision curve
analysis, according to the method proposed by Vickers
et al.20,21 In addition, we performed a sensitivity analysis
comparing the 2 scores’ predictive performance, using an on-
treatment analysis. A 2-sided P<0.05 was considered statis-
tically signiﬁcant. All analyses were performed using SPSS,
version 25.0 (IBM, NY) for MacOS and survIDINRI package for
R, version 3.3.1 for Windows.
Results
Among the original 7329 patients enrolled in the SPORTIF III
and V trials, 3665 (50.0%) were assigned to the warfarin arm.
According to data available, a total of 3550 patients (30.5%
women; median [interquartile range] age, 72 [66–77] years)
were available for this analysis. Baseline characteristics are
reported in Table 1. Hypertension was the most prevalent risk
factor (3167 patients [89.3%]), whereas previous bleeding was
reported in 200 (5.6%) and chronic kidney disease was
reported in 918 (25.9%). One ﬁfth (705 patients [19.9%]) of
the cohort used concomitant aspirin. Overall, there was a
good quality anticoagulation control, with a median (interquar-
tile range) time in therapeutic range of 68.2% (55.1%–79.6%).
At baseline, the median (interquartile range) HAS-BLED
score was 3 (2–4), with 2519 patients (71.0%) with a HAS-
BLED score ≥3. Using a GARFIELD-AF median score value,
2056 patients (57.9%) were categorized as high score and
1494 (42.1%) were categorized as low score.
Over a mean of 1.56 (SD, 0.38) years of follow-up, 127
major bleeding (2.29 per 100 patient-years), 168 major/
CRNM bleeding (3.03 per 100 patient-years), and 1450 any
bleeding (26.2 per 100 patient-years) outcomes were
recorded.
Kaplan-Meier analyses showed that patients with a HAS-
BLED score ≥3 had a higher cumulative risk of major bleeding
and major/CRNM bleeding outcomes compared with patients
with a HAS-BLED score <3 (Figure 1, top panels).
For GARFIELD-AF risk categories, the high-score category
showed a nonsigniﬁcant trend for major bleeding in the
higher-risk category compared with the low-score category
(P=0.069), whereas for the major/CRNM bleeding outcome,
the high-score category had a signiﬁcantly greater risk than
the low-score category (P=0.013) (Figure 1, bottom panels).
For the “any bleeding” outcome, patients with a HAS-BLED
score ≥3 had a higher cumulative risk compared with those
with a HAS-BLED score <3 (P<0.001), but no signiﬁcant
difference was found according to the GARFIELD-AF bleeding
risk categories (P=0.250) (Figure 2).
Survival and Predictive Analysis
Using a Cox regression model (Table 2), adjusted for sex and
type of AF, we found that the continuous HAS-BLED score was
signiﬁcantly associated with the occurrence of all the 3
bleeding outcomes, with an increase in relative risks ranging
from 13% to 31% (for any bleeding and major bleeding,
respectively) for each score point. The GARFIELD-AF bleeding
score was only signiﬁcantly associated with the major
bleeding outcome (hazard ratio, 1.39; 95% CI, 1.04–1.86).
Predictive analysis (Table 2), performed according to
C-indexes, indicated that both scores only had modest predic-
tive value, for the 3 bleeding outcomes (HAS-BLED, C-indexes
0.55–0.58; GARFIELD-AF C-indexes 0.56–0.57 for major and
major/CRNM bleeding, but nonsigniﬁcant for any bleeding). No
signiﬁcant differenceswere found between the 2 scores for their
respective C-indexes for major and major/CRNM bleeding.
Table 1. Baseline Characteristics
Characteristics Value (N=3550)
Age, median (IQR), y 72 (66–77)
Female sex, n (%) 1084 (30.5)
BMI, median (IQR), kg/m2 (n=3540) 28.1 (25.0–31.6)
CrCl, median (IQR), mL/min 79.7 (59.3–102.1)
Chronic AF, n (%) (n=3548) 3167 (89.3)
Hypertension, n (%) 2723 (76.7)
Diabetes mellitus, n (%) 833 (23.5)
Coronary artery disease, n (%) 1574 (44.3)
Stroke/TIA, n (%) 730 (20.6)
Heart failure, n (%) 1324 (37.3)
Previous bleeding, n (%) 200 (5.6)
Chronic kidney disease, n (%) 918 (25.9)
Aspirin use, n (%) 705 (19.9)
TTR, median (IQR), % 68.2 (55.1–79.6)
AF indicates atrial ﬁbrillation; BMI, body mass index; CrCl, creatinine clearance; IQR,
interquartile range; TIA, transient ischemic attack; TTR, time in therapeutic range.
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Discrimination and Reclassiﬁcation Analysis
On the basis of integrated discrimination improvement
analyses, the GARFIELD-AF bleeding score showed a non-
signiﬁcant decrease in the averaged sensitivity for major
bleeding (0.2%, P=0.318) and a nonsigniﬁcant increase in
the averaged sensitivity for major/CRNM bleeding (0.1%,
P=0.746) in comparison with the HAS-BLED score (Table 3).
Using net reclassiﬁcation improvement, there was a non-
signiﬁcant negative reclassiﬁcation against HAS-BLED for
major bleeding (4.2%, P=0.448) and a nonsigniﬁcant
positive reclassiﬁcation for major/CRNM bleeding (3.3%,
P=0.756). The GARFIELD-AF bleeding score had a signiﬁcantly
lower sensitivity and a negative reclassiﬁcation for any
bleeding compared with HAS-BLED, assessed by both
integrated discrimination improvement (1.1%, P<0.001)
and net reclassiﬁcation improvement (8.7%, P<0.001). This
demonstrated that, overall, the median improvement of the
GARFIELD-AF bleeding score was reduced almost in 2%
compared with the HAS-BLED score (1.6%, P<0.001).
We also tested the clinical usefulness and net beneﬁt of
the 2 scores using decision curve analyses (Figure 3). For
major bleeding and major/CRNM bleeding, the curves
corresponding to both models overlapped, suggesting no
apparent net beneﬁt of one model over the other. Only a slight
higher net beneﬁt was observed for HAS-BLED for the major
Figure 1. Kaplan-Meier curves for major and major/clinically relevant nonmajor (CRNM) bleeding for GARFIELD-AF (Global Anticoagulant in
the Field–Atrial Fibrillation) bleeding and HAS-BLED (Hypertension, Abnormal renal and liver function, Stroke, Bleeding, Labile INRs, Elderly,
Drugs or alcohol) scores.
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bleeding outcome. However, the HAS-BLED score graphically
demonstrated a net beneﬁt of 5% over the GARFIELD-AF
bleeding score for any bleeding.
Sensitivity Analysis
Throughout the entire follow-up period, a total of 804 (22.6%)
of patients interrupted warfarin treatment. A sensitivity
analysis on the predictive ability of HAS-BLED and GAR-
FIELD-AF bleeding scores based only on patients who
continued treatment was then performed (Table 4).
The HAS-BLED score modestly signiﬁcantly predicted all the
bleeding outcomes,with a slightly higher predictive capacity. The
GARFIELD-AF bleeding score did not predict major bleeding and
any bleeding outcomes but had marginal predictive capacity for
major/CRNM bleeding in this on-treatment analysis.
Comparing C-indexes, the HAS-BLED score had a signiﬁ-
cantly higher predictive capacity for the any bleeding outcome
(P<0.001).
Discussion
In this analysis, derived from a large international randomized
controlled trial, we showed that the HAS-BLED score had
modest predictive capacity for all the bleeding outcomes, but
was signiﬁcantly associated with all bleeding outcomes.
Conversely, the GARFIELD-AF bleeding score showed modest
predictive capacity for major and major/CRNM bleeding
outcomes but did not predict the any bleeding outcome.
Second, when comparing the more complex GARFIELD-AF
bleeding score with the simple HAS-BLED score, there was no
signiﬁcant advantage in terms of reclassiﬁcation and net
beneﬁt for major bleeding and major/CRNM bleeding;
however, the HAS-BLED score demonstrated a net beneﬁt
of 5% over the GARFIELD-AF bleeding score for the any
bleeding outcome. Finally, the on-treatment cohort analysis
shows that the HAS-BLED score signiﬁcantly predicted all the
bleeding outcomes studied, whereas the GARFIELD-AF score
only marginally predicted major/CRNM bleeding.
Figure 2. Kaplan-Meier curves for any bleeding for GARFIELD-AF (Global Anticoagulant in the Field–Atrial Fibrillation) bleeding and HAS-BLED
(Hypertension, Abnormal renal and liver function, Stroke, Bleeding, Labile INRs, Elderly, Drugs or alcohol) scores.
Table 2. Survival and Predictive Analysis for Bleeding Outcomes for GARFIELD-AF Bleeding and HAS-BLED Scores
Variable
HAS-BLED GARFIELD-AF
HR (95% CI) C-Index (95% CI) HR (95% CI) C-Index (95% CI)
Major bleeding 1.31 (1.14–1.51) 0.58 (0.56–0.60) 1.39 (1.04–1.86) 0.56 (0.54–0.57)
Major/CRNM bleeding 1.23 (1.09–1.39) 0.56 (0.54–0.58) 1.23 (0.99–1.54) 0.57 (0.55–0.58)
Any bleeding 1.13 (1.09–1.18) 0.55 (0.53–0.57) 1.05 (0.98–1.13) 0.51 (0.49–0.53)
CI indicates conﬁdence interval; CRNM, clinically relevant nonmajor; GARFIELD-AF, Global Anticoagulant in the Field–Atrial Fibrillation; HAS-BLED, Hypertension, Abnormal renal and liver
function, Stroke, Bleeding, Labile INRs, Elderly, Drugs or alcohol; HR, hazard ratio.
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Incident bleeding events among patients with AF taking
anticoagulants are a feared complication when prescribing
OACs,22 and overestimating patients’ bleeding risk leads to
underprescription of OACs.23 Data from the ORBIT-AF (Out-
comes Registry for Better Informed Treatment of AF) study show
that history of bleeding was one of the most prevalent reasons
for not prescribingOACs,24 aswell as for OACdiscontinuation.25
The impact of bleeding events, irrespective of the type, can
be strongly relevant in the clinical course and decision making
for patients with AF. Major bleeding events can lead to a
signiﬁcant risk of death and major adverse outcomes, both
short- and long-term.26,27 Also, all bleeding events are
associated with an impaired quality of life.28 Irrespective of
type, patients experiencing a bleeding event are more likely to
discontinue OAC treatment,29 which is associated with an
increased risk for clinically signiﬁcant events.30
Nonetheless, a high risk of bleeding should not be a reason
to withhold OAC prescription.8 Guidelines on management of
AF recommend assessing baseline bleeding risk to evaluate
speciﬁc interventions to control and reduce this risk.4 Also,
bleeding risk assessment should be routinely repeated at
follow-up visits and modiﬁable risks should be managed
appropriately.5
Thus far, the HAS-BLED score has been validated in several
cohorts and is able to predict major bleeding in various
clinical settings.31–34 Several studies reported about the
comparison between HAS-BLED and other bleeding risk
scores in vitamin K antagonist-treated cohorts.31,35–39 These
studies all demonstrate a modest predictive capacity for these
clinical bleeding risk scores, although most analyses reported
that the HAS-BLED score performs best.31,36,38 In particular,
high-risk patients (HAS-BLED score ≥3) have a signiﬁcantly
Figure 3. Decision curve analysis according to GARFIELD-AF (Global Anticoagulant in the Field–Atrial Fibrillation) bleeding and HAS-BLED
(Hypertension, Abnormal renal and liver function, Stroke, Bleeding, Labile INRs, Elderly, Drugs or alcohol) scores. CRNM indicates clinically
relevant nonmajor.
Table 3. IDI, NRI, and Median Improvement Between GARFIELD-AF Bleeding and HAS-BLED Scores
Variable
GARFIELD-AF vs HAS-BLED
IDI 95% CI P Value NRI 95% CI P Value Median Improvement 95% CI P Value
Major bleeding 0.002 0.007/0.003 0.318 0.042 0.189/0.087 0.448 0.002 0.010/0.005 0.308
Major/CRNM bleeding 0.001 0.005/0.007 0.746 0.033 0.094/0.129 0.756 0.001 0.007/0.009 0.378
Any bleeding 0.011 0.019/0.005 <0.001 0.087 0.131/0.056 <0.001 0.016 0.030/0.001 <0.001
CI indicates conﬁdence interval; CRNM, clinically relevant nonmajor; GARFIELD-AF, Global Anticoagulant in the Field–Atrial Fibrillation; HAS-BLED, Hypertension, Abnormal renal and liver
function, Stroke, Bleeding, Labile INRs, Elderly, Drugs or alcohol; IDI, integrated discrimination improvement; NRI, net reclassiﬁcation improvement.
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higher risk of major bleeding, as demonstrated in several
studies.31,40 In a Spanish real-world cohort, for example, a
HAS-BLED score ≥3 demonstrated signiﬁcant predictive
ability (C-index [95% CI], 0.68 [0.65–0.71]).31 Similar data,
derived from the Loire Valley AF Project, showed that patients
with a HAS-BLED score ≥3 reported a higher rate of major
bleeding, with a signiﬁcantly increased risk (hazard ratio, 3.57;
95% CI, 2.59–4.92) compared with patients with a HAS-BLED
score of 2 and a HAS-BLED score of 0 to 1.40
The GARFIELD-AF bleeding score has been recently derived
from the GARFIELD-AF registry study.13 In the original
derivation cohort, the GARFIELD-AF bleeding score performed
modestly (C-index, 0.66; 95% CI, 0.62–0.69), with marginal
improvement compared with the HAS-BLED score (C-index,
0.64; 95% CI, 0.61–0.68).13 When applied in an external
validation cohort, derived from the ORBIT-AF registry study,
the new model performed less well (C-index, 0.61; 95% CI,
0.59–0.63 for the 3-year major bleeding risk).13 Even if the
GARFIELD-AF bleeding score is intended to be used as a
continuous score, data from the derivation cohort showed
that on stratifying according to the median value, those
patients in the high-score group had a higher cumulative
incidence, compared with those patients in the low-score
group.13 In addition, the statistical model used to derive the
score cannot be easily compiled at the patient’s bedside or in
outpatient clinics, and the model proposed does not consider
some established bleeding risk factors and strong
predictors.41 This aspect likely affects the predictive abilities
of the GARFIELD-AF bleeding score in identifying any bleeding
occurrence.
The ability of the scores to correctly identify patients more
likely to experience a bleeding event allows us to properly ﬂag
up those high-risk patients to treat the modiﬁable bleeding
risks and to help schedule those patients for early review and
follow-up (eg, 4 weeks rather than 4–6 months)8,42 to
ultimately minimize the occurrence of any bleeding event
throughout the long-term observation.
This study represents the ﬁrst external independent
validation of the new prognostic score, in a clinical trial
cohort with adjudicated bleeding outcomes. Our data clearly
showed that irrespective of the type of bleeding, the
GARFIELD-AF bleeding score performed only modestly in
predicting bleeding outcomes and was not predictive of any
bleeding. At the cost of reduced ease and practicality, the
GARFIELD-AF also did not show improvement in the discrim-
ination or reclassiﬁcation of bleeding risk. In the prediction of
any bleeding outcome, the HAS-BLED score showed a
signiﬁcant net beneﬁt compared with the GARFIELD-AF score,
using decision curve analysis. This article provides needed
evidence in the context of reassuring clinicians that the use of
an established (and largely validated) simple score (ie, HAS-
BLED) remains best, instead of using complex new scores
with limited additional advantages.
Limitations
This study is mainly limited by its post hoc retrospective nature.
Given that the study cohort was derived from a randomized
controlled trial, all bleeding risk factors were recorded and
managed, probably resulting in a lower rate of bleeding events
compared with the real-life populations. Furthermore, the
exclusion of patients with liver disease from the original cohort,
as well as the exclusive use of warfarin as an OAC treatment,
may somewhat limit the generalizability of our results.
Conclusions
The algorithm-based GARFIELD-AF bleeding score did not show
any signiﬁcant improvement in bleeding risk prediction for
major and major/CRNM bleeding compared with the simple
HAS-BLED score. For clinical usefulness in prediction of any
bleeding, the HAS-BLED score showed a signiﬁcant net beneﬁt
compared with the GARFIELD-AF score. The use of a simple,
easy to compile, and accurate score, such as the HAS-BLED
score, is pivotal to streamline the bleeding risk evaluation,
favor the management of modiﬁable bleeding risk factors, and
ultimately reduce the occurrence of any bleeding event.
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Major bleeding 0.60 (0.53–0.68) 0.55 (0.47–0.63) 0.352
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bleeding
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Table S1. Major bleeding rates according to HAS-BLED score as reported in 






Major Bleeding for  
100 patient-years 
0 798 9 1.13 
1 1286 13 1.02 
2 744 14 1.88 
3 187 7 3.74 
4 46 4 8.70 
5 8 1 12.50 
6 2 0 0.0 
7 - - - 
8 - - - 













1. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel 
user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in 
patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093–
100. 
 
 
